150 related articles for article (PubMed ID: 10994377)
1. [Monitoring of serum olanzapine during antipsychotic treatment].
Linnet K; Olesen OV
Ugeskr Laeger; 2000 Sep; 162(36):4802-5. PubMed ID: 10994377
[TBL] [Abstract][Full Text] [Related]
2. Differential olanzapine plasma concentrations by sex in a fixed-dose study.
Kelly DL; Conley RR; Tamminga CA
Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
Olesen OV; Linnet K
Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
[TBL] [Abstract][Full Text] [Related]
4. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
Linnet K; Olesen OV
Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636
[TBL] [Abstract][Full Text] [Related]
5. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Rao ML; Hiemke C; Grasmäder K; Baumann P;
Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
[TBL] [Abstract][Full Text] [Related]
6. Influence of fluoxetine on olanzapine pharmacokinetics.
Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
[TBL] [Abstract][Full Text] [Related]
7. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.
Olesen OV; Poulsen B; Linnet K
Ther Drug Monit; 2001 Feb; 23(1):51-5. PubMed ID: 11206044
[TBL] [Abstract][Full Text] [Related]
8. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.
Khan M; Farver D
S D J Med; 2000 Feb; 53(2):65-7. PubMed ID: 10731859
[TBL] [Abstract][Full Text] [Related]
9. Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection.
Gervasini G; Vizcaíno S; Herráiz AG; Benítez J; Carrillo JA
Clin Chem; 2003 Dec; 49(12):2088-91. PubMed ID: 14633885
[No Abstract] [Full Text] [Related]
10. [Olanzapine in the first episode of schizophrenia in young adults].
Dabkowska M
Psychiatr Pol; 2002; 36(6 Suppl):235-41. PubMed ID: 12647444
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
[No Abstract] [Full Text] [Related]
13. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection.
Aravagiri M; Ames D; Wirshing WC; Marder SR
Ther Drug Monit; 1997 Jun; 19(3):307-13. PubMed ID: 9200772
[TBL] [Abstract][Full Text] [Related]
14. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring.
Llorca PM; Coudore F; Corpelet C; Buyens A; Hoareau M; Eschalier A
Clin Chem; 2001 Sep; 47(9):1719-21. PubMed ID: 11514415
[No Abstract] [Full Text] [Related]
15. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants.
Gardiner SJ; Kristensen JH; Begg EJ; Hackett LP; Wilson DA; Ilett KF; Kohan R; Rampono J
Am J Psychiatry; 2003 Aug; 160(8):1428-31. PubMed ID: 12900304
[TBL] [Abstract][Full Text] [Related]
16. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
Weimer E; Braus DF; Cavus I; Thome J
Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436
[TBL] [Abstract][Full Text] [Related]
17. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
[TBL] [Abstract][Full Text] [Related]
18. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine.
Boulton DW; Markowitz JS; DeVane CL
J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(2):319-23. PubMed ID: 11499485
[TBL] [Abstract][Full Text] [Related]
19. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
[TBL] [Abstract][Full Text] [Related]
20. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Ramasubbu R; Ravindran A; Lapierre Y
Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
